UNSPSC 51284303: Thiamphenicol

This classification denotes a protein synthesis inhibitor and antibiotic with the molecular formula C12H15Cl2NO5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FLQ7571NPM, chemically known as (+-)-threo-2,2-dichloro-n-(beta-hydroxy-alpha-(hydroxymethyl)-p-(methylsulfonyl)phenethyl)acetamide but generally known as thiamphenicol, which bears US NIH Compound Identifier 5433. European Medicines Agency schedules Thiamphenicol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10970MIG.

UNSPSC 51284303 Thiamphenicol, a Commodity code, nominally names a specific antibiotic pharmaceutical but the recent state and local activity tagged to this code does not reflect procurement of thiamphenicol itself. Instead, the code appears in solicitations for broader pharmaceutical and medical supply procurement — naloxone, generic multi-source drugs, over-the-counter products, and emergency medical consumables — suggesting either a data-tagging mismatch or that the code is being used as a catch-all for pharmaceutical inventory management. State and local buyers under this code include county health departments, state health and human services agencies, fire departments, and multi-state cooperative purchasing alliances. The mix reflects both direct-buy procurement by individual jurisdictions and aggregated purchasing through cooperative mechanisms serving multiple states and localities.

Recent activity spans Florida, Texas, Minnesota, and Oregon. Representative solicitations include Seminole County, Florida's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (IFB60459723LAS, response due July 26, 2023); the City of Tampa's invitation to bid for 169 line items of medical and first aid supplies for its Fire Department Rescue Division with an estimated contract value of $700,000 and a response deadline of March 13, 2026, restricted to certified Small Local Business Enterprises with a 5 percent bid discount; the Texas Health and Human Services Commission's Request for Information on direct-to-manufacturer prescription programs (RFI HHS0017013, posted April 3, 2026); and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and over-the-counter products serving participating state and local facilities across multiple jurisdictions (RFP S1070000015802, due March 26, 2026). The Tampa and MMCAP solicitations explicitly require compliance with cGMP, DSCSA, FDA standards, and substantial insurance coverage including general liability and network security liability.